Exact Sciences (EXAS) edged higher by 0.5% amid reports the HSR waiting period for its planned sale to Abbott Laboratories (ABT) expired.
The HSR waiting period for the deal was set to expire on Thursday. There was at least one report circulating that HSR had indeed expired, meaning that the $105 a share deal had cleared antitrust scrutiny, traders told Seeking Alpha on Friday.
Exact Sciences (EXAS) and Abbott (ABT) didn’t immediately respond to Seeking Alpha’s email request for comment.
Abbott (ABT) agreed to acquire cancer-screening company Exact Sciences (EXAS) in an all-cash deal valued at $21 billion in November.
Shares of Abbott ticked higher by 0.5%.